Journal of Biomedical and Clinical Research 8(2): 104-111, doi: 10.1515/jbcr-2015-0159
Alcohol Septal Ablation
, Sotir T. Marchev, Boyko D. Kuzmanov© , Sotir Marchev, Boyko Kuzmanov. This is an open access article distributed under the terms of the Creative Commons Attribution License (CC BY-NC-ND 4.0), which permits to copy and distribute the article for non-commercial purposes, provided that the article is not altered or modified and the original author and source are credited. Citation:
Marchev ST, Kuzmanov BD (2015) Alcohol Septal Ablation. Journal of Biomedical and Clinical Research 8(2): 104-111. https://doi.org/10.1515/jbcr-2015-0159 |  |
Abstract
Since 1994, alcohol septal ablation (ASA) has been used as a minimally invasive treatment of patients with hypertrophic obstructive cardiomyopathy, resistant to conservative medical therapy. This catheter-based intervention consists of injecting absolute alcohol in a septal perforator to induce infarction of the hypertrophied septum and thus diminish the left ventricle outflow tract obstruction. This reduction of the gradient is associated with reduction of symptoms and left ventricle remodeling. The procedure was improved after the introduction of myocardial contrast echocardiography for visualization of the area at risk of infarction and reduction of the alcohol amount. Major complications of ASA are rare but centers with experience have reported conduction disorders - about 10% of patients needed permanent pacing because of complete AV block. Large randomized prospective studies have not yet compared alcohol septal ablation to the gold standard for treatment of hypertrophic obstructive cardiomyopathy - surgical myomectomy.
Keywords
hypertrophic cardiomyopathy, left ventricular outflow obstruction, alcohol septal ablation